Cases & Deals

  • Home
  • Practices
  • Sumitomo Dainippon Pharma concludes joint development and license agreement with SanBio for North America for SB623

Share

Sumitomo Dainippon Pharma concludes joint development and license agreement with SanBio for North America for SB623

September 2014

Client(s) Sumitomo Dainippon Pharma Co., Ltd.

Jones Day advised Sumitomo Dainippon Pharma Co., Ltd. in a joint development and license agreement for exclusive marketing rights in the U.S. and Canada for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio Co., Ltd.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.